Yesterday Companion Medical announced the commercial launch of their smart pen the InPen®. Per a company issued press release;
“Companion Medical, a leader in the development of advanced technology to improve diabetes care, announced today that it has begun commercial sales of the InPen® system in the United States. InPen is available by prescription only and is a covered benefit under many insurance plans. The InPen is for use with U-100 Lilly Humalog® and Novo Nordisk Novolog® rapid-acting insulin and indicated for persons aged 12 years and older.”
Also, yesterday Lilly (NYSE: LLY) announced a deal with Rimidi . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.